Compare Southwest Airlines Co (LUV) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Pfizer Inc — how do they compare? Southwest Airlines Co trades at $40.96 (market cap $20.23B), while Pfizer Inc trades at $27.83 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 7.8× Southwest Airlines Co's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 65 Days and Pfizer Inc for 158 Days on average.
| LUV | PFE | |
|---|---|---|
Market Cap | $20.23B | $158.56B |
Volume | 14,560,422 | 44,138,282 |
Sector | Industrials | Health |
52-Week High | $54.80 | $29.02 |
52-Week Low | $29.67 | $23.67 |
Typical Hold Time | 65 Days | 158 Days |
Enterprise Value | $23.33B | $210.06B |
Dividend Yield | 1.74% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $41.72, down 1.72% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth from $28.06B in 2025 to projected $30.1B in 2026, though net margins remain thin at 2.78%. Recent earnings show volatility with a Q2 2026 beat but Q1 2026 miss, while analyst consensus leans slightly bullish with a $49.61 price target representing 19% upside potential.
LUV presents a transformation story with new revenue initiatives driving growth, but faces headwinds from high fuel costs and competitive pressures. The stock offers value with reasonable P/E of 26.08 and P/S of 0.73, though investors should monitor execution of commercial initiatives and fuel cost management. Near-term catalyst includes Q3 2026 earnings release on October 21, 2026.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
